H......IMO studies in peer reviewed journals(which would include the Jelis and Cherry studies) are subjects for "truthful and non misleading" speech. Anecdotal evidence would not qualify, even though impressive.
HDG, did JT mention Amarin was working with the FDA to level the playing field for Vascepa in a recent CC (Q3 or Q22015?). I am sure you can dig up the exact quote. I hope the 1A settlement talk will include the level the playing field Vs fibrates and niacin if it's not about ANCHOR or R-IT.